Author

Jeffrey D. Kearns

Forma Therapeutics (United States)ORCID 0000-0001-7261-5096Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

A.P. TurnbulliD· 1 shared Adán Pinto-FernándeziD· 1 shared Akane KawamuraiD· 1 shared Anthony C. VarcaiD· 1 shared Benedikt Mathias KessleriD· 1 shared Cameron Bell· 1 shared Christopher J. DinsmoreiD· 1 shared Claire HerideiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A.P. TurnbullORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivPreprintJun 18, 2026

Refined USP25/28 inhibitors with enhanced selectivity towards c-Myc driven squamous lung cancer cells

Adán Pinto-Fernández, Claire Heride, A.P. Turnbull…·Benedikt Mathias Kessler

This study develops refined USP25/28 inhibitors that selectively target c-MYC driven squamous lung cancer cells with reduced off-target effects and toxicity.

DOI 10.64898/2026.03.17.712179

humanproteomics

𝕏 PostBluesky